Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT03239171

Bioinformation Therapy for Lung Cancer

Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Lung Cancer

Sponsor: Fuda Cancer Hospital, Guangzhou

Interventions Cancer ablation Life information rehabilitation therapy

Updated 6 times since 2017 Last updated: Jan 23, 2019 Started: Sep 2, 2017 Primary completion: Sep 2, 2018 Completion: Sep 2, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03239171, this PHASE2/PHASE3 trial focuses on Small-cell Lung Cancer and remains completed. Sponsored by Fuda Cancer Hospital, Guangzhou, it has been updated 6 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Feb 2019 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Aug 2017 — Jun 2018 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuda Cancer Hospital, Guangzhou
Shengxin Biotechnology Institute, Beijing

Data source: Fuda Cancer Hospital, Guangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China